Regeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon. 

AstraZeneca Plc said the company’s asthma treatment Fasenra for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.

Lyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.